A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas

Burton, Eric; Walker, Erin; Boris, Lisa; Reyes, Jennifer; Fernandez, Kelly; Wall, Kathleen; Wu, Jing; T. Schmidt, Keith; D. Figg, William; Brown, Desmond

doi:10.1101/2025.08.18.25333496

Public

A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas

Published in medRxiv • Aug 21, 2025

Authors:

Eric Burton

Erin Walker

Lisa Boris

Abstract

ABSTRACT Background LB100 is a protein phosphatase 2A (PP2A) inhibitor. Glioma models show inhibition of PP2A by LB100 causes cell death. Whether LB100 crosses the human blood brain barrier (BBB) is unknown. We sought to determine the pharmacokinetic (PK) properties of LB100 in human subject gliomas...

Subject

Pharmacokinetics

Glioma

Cmax

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!